Thus, it is essential to identify this subgroup of DLBCL who may acquire more benefits from the JAK2 and PD-L1 signaling inhibition, and JAK2 amplification detection by MLPA would be feasible in routine practice. This evidence concerns the gene JAK2 and diffuse large B-cell lymphoma.